Table 1.

Inhibitory concentrations of CT32228 in proliferation assays

A. Antiproliferative activity of CT32228 against a panel of hematopoietic cell lines
Cell lineIC50 (nmol/L)IC80 (nmol/L)
32D6095
32DBCR-ABL80112
Mo7e100150
Mo7eBCR-ABL105165
AR230-s2335
AR230-r185108
BaF/388125
BaF/BCR-ABL85110
BaF/BCR-ABL (WEHI)105>250
BaF/BCR-ABL-r190112
BaF/BCR-ABLY253F92135
BaF/BCR-ABLT315I85122
BaF/BCR-ABLM351T82120
BaF/BCR-ABLH396R89125
K56256115
KCL-2290225
Lama8462120
B. Antiproliferative activity of CT32228 against primary hematopoietic progenitor cells.
IC50 (nmol/L)
IC80 (nmol/L)
Normal
CML
Normal
CML
CFU-GM, plus GF190240410590
CFU-GM, no GF17070>2,000110
  • NOTE: (A) Given are drug concentrations that induce 50 (IC50) or 80% (IC80) growth inhibition compared with untreated control as derived from MTS/MTT assays. Given are means of three independent experiments. (B) Given are drug concentrations that induce 50 (IC50) or 80% (IC80) growth inhibition of CFU-GM compared with untreated control as derived from colony-forming assays. Given are means of five independent patient samples (see Fig. 2). Conditions with and without growth factors are listed (plus GF and no GF).